Browse by author
Lookup NU author(s): Professor Andrew Pearson,
Dr Michael Reid,
Emeritus Professor Alan Craft
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count. A partial response was seen in two patients, and a very good partial response, in one patient. Extensive blood-component support was required. Non-haemopoietic toxicity was severe and led to treatment delays in two patients. Ifosfamide-related encephalopathy was seen in one patient and nephrotoxicity, in two patients. Mucositis was severe in two patients, may have contributed to the high rate of sepsis observed, and precluded the use of doxorubicin in one patient. As ifosfamide and doxorubicin were felt to be responsible for much of the toxicity, a subsequent schedule did not include these agents.
Author(s): Lowis, S. P., Pearson, A. D. J., Reid, M. M., Craft, A. W.
Publication type: Note
Publication status: Published
Journal: Cancer Chemotherapy and Pharmacology
Print publication date: 01/09/1993
ISSN (print): 0344-5704
ISSN (electronic): 1432-0843
PubMed id: 8431977